| Author/Editor | Strauch, Rika | |
| Title | Delež proti ciprofloksacinu odpornih klic Citrobacter freundii pri bolnikih z akutno levkemijo, ki prejemajo ciprrofloksacin zaradi preprečevanja bakterijskih okužb | |
| Type | monografija | |
| Place | Ljubljana | |
| Publisher | Medicinska fakulteta | |
| Publication year | 2002 | |
| Volume | str. 38 | |
| Language | slo | |
| Abstract | BACKGROUND: Patients with acute leukemia are treated at the Department of Haematology in Clinical Center of Ljubljana. Due to cytotoxic chemoterapy, aplasia of bone marrow is inevitable, therefore these patients are at high risk for bacterial and fungal infection. Ciprofloxacin is used for infection prophylaxis in neutropenic patients. We have noticed a rise in the number of ciprofloxacin-resistant strains of C. freundii (CipR C. freundii) and decided to find out if ciprofloxacin is still usable in this setting. AIM: To determine whether or not ciprofloxacin-resistant strains of C. freundii are more prevalent in our department compared to data in literature and to asses the efficacy of ciprofloxacin in preventing bacterial infections. HYPOTHESIS: We believe that ciprofloxacin-resistant strains of C. freundii and other Enterobacteriaceae is lower despite the observed rise, compared to data from literatur. We believe that ciprofloxacin prophylaxis suffices. METHODS: 45 patients with acute leukemia were admitted to our department during last year. C. freundii was isolated in 11 patients (24, 4%). We determined the proportion of ciprofloxacin-resistant strains in C. freundii and other Enterobacteriacea. We also determined the proportion of strains who produce extended spectrum beta-lactamases (ESBL). The number of isolates was calculated on a patient or a chemotherapy cycle. Susceptibility testing was done by NCCLS standards by the disc diffusion method and minimal inhibitory concentration (MIC). RESULTS: We isolated C. freundii in 24% (of 45) patients.13% (of 11) patients had ESBL+ C. freundii, and the same was true for CipR C. freundii. 13% (of 11) patients had strain that was CipR C. freundii that produced ESBL. Concerning the isolates, 37 (out of 292) were C. freundii. 22 (of 37) were CipR C. freundii and almost all (21 out of 22) were ESBL producers. (Abstract truncated at 2000 characters). | |
| Descriptors | LEUKEMIA, LYMPHOCYTIC, ACUTE CIPROFLOXACIN DRUG RESISTANCE, MICROBIAL CITROBACTER FREUNDII ENTEROBACTERIACEAE INFECTIONS BETA-LACTAMASES |